Enrichment Materials: Complex Psychopharmacology Case

Abstract

This enrichment package provides advanced clinical materials supporting the complex psychopharmacology case review of a 35-year-old female with Bipolar II Disorder, ADHD, Generalized Anxiety Disorder, and Alcohol Use Disorder in remission. The materials include: (1) expanded evidence base with primary literature, (2) pharmacokinetic analysis of the current regimen, (3) alternative treatment algorithms, (4) case-based learning modules, and (5) regulatory/liability considerations. Target audience: advanced practitioners seeking deeper understanding of rational polypharmacy in mood and attention disorders.

1. Expanded Evidence Base

1.1 Lamotrigine in Bipolar Depression: Primary Literature

Calabrese JR, et al. (1999). A double-blind, placebo-controlled, multicenter trial of lamotrigine as maintenance treatment for bipolar I and II depression. Journal of Clinical Psychiatry.

Key Findings: Lamotrigine 200mg demonstrated superiority to placebo in delaying time to intervention for mood episodes. Subtherapeutic dosing (50mg, 100mg) showed intermediate effects suggesting dose-response relationship. No evidence for additional efficacy above 200mg.

Clinical Application: Current patient at 100mg is below evidence-based target for acute bipolar depression. Titration to 200mg supported by RCT data.

Geddes JR, et al. (2009). Lamotrigine for acute bipolar depression: a systematic review and meta-analysis. Lancet.

Key Findings: Meta-analysis of 5 RCTs (n=1,072) showed lamotrigine superior to placebo for bipolar depression with effect size 0.47. No difference between Bipolar I and II subgroups. Onset of action 3-4 weeks.

Goodwin GM, et al. (2016). Evidence-based guidelines for treating bipolar disorder: Revised third edition. Journal of Psychopharmacology.

Recommendations: Lamotrigine first-line for bipolar depression maintenance. Target dose 200mg/day (lower doses may be subtherapeutic). Taper over 2 weeks if discontinuing (rebound risk).

1.2 Stimulant Formulation Pharmacokinetics

Formulation	Tmax	Duration	Peak: Trough Ratio	Clinical Implication
Adderall IR 30mg	3 hours	4-6 hours	8:1	Significant peaks/troughs; afternoon crash
Adderall XR 30mg	7 hours	10-12 hours	3:1	Smoother coverage; sustained efficacy
Lisdexamfetamine 30mg	3.5 hours	10-12 hours	2:1	Lowest peak/trough; prodrug design

Source: Ermer et al. (2011). Pharmacokinetics of lisdexamfetamine dimesylate in healthy adults. Journal of Clinical Pharmacology.

1.3 Antidepressants in Bipolar Disorder: Risk Quantification

Tondo L, et al. (2010). Depression and antidepressants in bipolar disorder. International Journal of Neuropsychopharmacology.

Switch Risk Data: Antidepressant monotherapy switch rates: TCAs 11%, venlafaxine 7%, SSRIs 4%, bupropion 2%. Risk highest in first 8 weeks. Mood stabilizer co-treatment reduces risk by 60%.

Pacchiarotti I, et al. (2013). The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. American Journal of Psychiatry.

Recommendations: Avoid antidepressant monotherapy. SNRIs (venlafaxine, duloxetine) carry higher switch risk than SSRIs. Use with mood stabilizer and close monitoring acceptable for breakthrough depression.

2. Pharmacokinetic Analysis

2.1 Drug-Drug Interaction Matrix

Drug Pair	Mechanism	Clinical Effect	Management
Lamotrigine + Estrogen (OCP)	Induction of UGT1A4	↓ Lamotrigine levels ~50%	Increase lamotrigine dose; monitor levels if available
Lamotrigine + Valproate	Inhibition of glucuronidation	↑ Lamotrigine levels 2x	Reduce lamotrigine 50%; slower titration
Naltrexone + Opioids	Mu-receptor antagonism	Precipitated withdrawal	Absolute contraindication; ensure 7-10 day opioid-free
Venlafaxine + Tramadol	Dual SNRI effect	Serotonin syndrome risk	Avoid combination; document allergy
Propranolol + Stimulants	Beta-blockade masks tachycardia	Missed cardiovascular side effects	Monitor BP, not just HR; watch for masking

2.2 Hepatic Metabolism Burden

CYP2D6 Substrates: Venlafaxine (minor), doxepin

CYP3A4 Substrates: None in current regimen

Glucuronidation: Lamotrigine (primary), doxepin (minor)

Renal Excretion: Gabapentin (100%), naltrexone metabolites

Clinical Implication: Current regimen has low risk for CYP-mediated drug interactions. Lamotrigine metabolism via UGT not affected by typical inhibitors. Naltrexone hepatic metabolism requires monitoring in liver disease but minimal interaction profile.

3. Alternative Treatment Algorithms

3.1 Alternative: Lurasidone-Based Approach

Rationale: FDA-approved for bipolar depression; no switch risk; no weight gain.

Current Regimen	Alternative Regimen	Trade-offs
Venlafaxine 187.5mg	Lurasidone 40mg	↓ Switch risk; ↑ Cost; requires daily dosing
Lamotrigine 100mg	Lurasidone covers mood stabilization	Simplifies regimen; removes lamotrigine titration risk

Why Not Implemented: Current regimen working; switching stable medication introduces new risks; venlafaxine plus optimized lamotrigine provides equivalent efficacy with established tolerability.

3.2 Alternative: Bupropion Substitution

Rationale: Lower switch risk than venlafaxine; ADHD benefits.

Parameter	Venlafaxine	Bupropion
Switch risk in bipolar	7%	2%
ADHD efficacy	Minimal	Moderate
Anxiety efficacy	Strong	Neutral/may worsen

Contraindication: Patient has prominent anxiety (GAD-7: 11). Bupropion's anxiety-neutral/worsening profile makes it poor fit despite lower switch risk.

4. Case-Based Learning Modules

4.1 Clinical Vignette: Medication-Induced Mania Recognition

Scenario: Four weeks after venlafaxine increase to 225mg, patient presents reporting "I feel fantastic! I've decided to go back to school, start a business, and I'm only sleeping 4 hours a night but I have so much energy!"

Questions for Reflection:

Is this antidepressant response or emerging hypomania?
What collateral information would clarify?
Immediate management steps?
Long-term medication adjustment?

Key Distinguishing Features: Elevated mood + functional impairment = mania. Elevated mood + improved function = antidepressant response. Patient's grandiosity (business, school) and sleep reduction suggest mania despite subjective "great" feeling.

4.2 Clinical Vignette: Stevens-Johnson Syndrome Recognition

Scenario: Three weeks into lamotrigine titration (now at 125mg), patient calls reporting "a few small red bumps on my chest and I've had a fever for two days."

Learning Points:

Any rash with lamotrigine = stop immediately
SJS typically preceded by prodrome (fever, malaise, sore throat)
Mortality 5-10% if SJS; 30% if TEN
Rechallenge never appropriate after SJS/TEN

Action Required: Immediate discontinuation, urgent dermatology consultation, possible hospitalization. Document patient education: "Call immediately for any rash, do not wait for appointment."

5. Regulatory and Liability Considerations

5.1 Informed Consent Documentation

Required Disclosures for This Regimen:

Medication	Risk	Documentation Requirement
Lamotrigine	Stevens-Johnson syndrome	Patient verbalized understanding to stop for rash; emergency contact provided
Naltrexone	Hepatotoxicity	LFT monitoring schedule explained; symptoms reviewed
Stimulants	Diversion, misuse	Controlled substance agreement signed; lockbox recommended
Venlafaxine	Mood elevation	Family collateral recommended; warning signs reviewed

5.2 Collaborative Practice Agreement Considerations

Scope of Practice: APRN prescribing within collaborative agreement with psychiatric MD.

Key Documentation for Chart Review:

Rationale for each medication clearly articulated
Alternative options considered and declined documented
Monitoring protocols explicitly stated
Consultation sought for high-risk decisions
Patient preference incorporated into shared decision-making

6. Supplementary Assessment Tools

6.1 Recommended Rating Scales

PHQ-9: Depression severity (current: baseline for monitoring)
GAD-7: Anxiety severity (current: 11 — moderate)
ASRS-v1.1: ADHD symptoms (establish baseline before stimulant change)
YMRS: Young Mania Rating Scale (if any mood elevation suspected)
AUDIT-C: Alcohol use screening (each visit)
AIMS: Abnormal Involuntary Movement Scale (quarterly)
BES: Binge Eating Scale (formalize BED assessment)
Nightmare Frequency Questionnaire: Quantify prazosin response

6.2 Laboratory Monitoring Protocol

Parameter	Baseline	Follow-up	Rationale
CBC	Required	Annually	Naltrexone, medication effects
CMP (incl LFTs)	Required	1mo, 3mo, then q6mo	Naltrexone hepatotoxicity
Urinalysis	Consider	Annually	Baseline kidney function
Pregnancy test	If applicable	Ongoing if applicable	Teratogenicity of several agents